Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO(R)’s long-term efficacy, safety and mechanistic insights in fatigue
Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO(R)'s long-term efficacy, safety and mechanistic insights in fatigue GlobeNewswire November 07, 2025 Interim data from the IQIRVO(R) (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in improvement of fatigue and pruritus […]